BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Rating) CEO Vimal Mehta sold 30,000 shares of the stock in a transaction on Friday, December 16th. The stock was sold at an average price of $19.44, for a total transaction of $583,200.00. Following the completion of the sale, the chief executive officer now owns 9,957 shares in the company, valued at approximately $193,564.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
BioXcel Therapeutics Price Performance
BTAI traded down $0.05 during midday trading on Monday, hitting $20.00. 287,137 shares of the company traded hands, compared to its average volume of 454,671. The company has a current ratio of 10.34, a quick ratio of 10.28 and a debt-to-equity ratio of 0.72. The company has a market capitalization of $560.44 million, a price-to-earnings ratio of -4.10 and a beta of 1.30. BioXcel Therapeutics, Inc. has a 52-week low of $8.80 and a 52-week high of $24.57. The business has a 50 day simple moving average of $14.34 and a two-hundred day simple moving average of $13.85.
BioXcel Therapeutics (NASDAQ:BTAI – Get Rating) last posted its quarterly earnings results on Thursday, November 10th. The company reported ($1.49) earnings per share for the quarter, missing the consensus estimate of ($1.34) by ($0.15). The firm had revenue of $0.14 million for the quarter, compared to analysts’ expectations of $3.05 million. On average, equities analysts forecast that BioXcel Therapeutics, Inc. will post -5.31 earnings per share for the current fiscal year.
Hedge Funds Weigh In On BioXcel Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the business. Point72 Hong Kong Ltd purchased a new position in shares of BioXcel Therapeutics in the second quarter worth about $50,000. Quantbot Technologies LP acquired a new stake in BioXcel Therapeutics during the third quarter worth about $57,000. Amalgamated Bank acquired a new stake in BioXcel Therapeutics during the first quarter worth about $59,000. Game Plan Financial Advisors LLC acquired a new stake in BioXcel Therapeutics during the second quarter worth about $142,000. Finally, Virtus ETF Advisers LLC increased its position in BioXcel Therapeutics by 46.3% during the second quarter. Virtus ETF Advisers LLC now owns 11,284 shares of the company’s stock worth $149,000 after purchasing an additional 3,571 shares during the last quarter. 45.32% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of research firms have recently weighed in on BTAI. Canaccord Genuity Group increased their price objective on shares of BioXcel Therapeutics from $75.00 to $76.00 and gave the stock a “buy” rating in a research note on Friday, November 11th. Guggenheim cut their price objective on shares of BioXcel Therapeutics from $28.00 to $25.00 and set a “buy” rating on the stock in a research note on Friday, November 11th. The Goldman Sachs Group upgraded shares of BioXcel Therapeutics from a “sell” rating to a “neutral” rating and set a $16.00 price objective on the stock in a research note on Thursday, December 1st. HC Wainwright lowered their price target on shares of BioXcel Therapeutics from $110.00 to $85.00 and set a “buy” rating on the stock in a report on Wednesday, August 24th. Finally, Canaccord Genuity Group increased their price target on shares of BioXcel Therapeutics from $75.00 to $76.00 and gave the stock a “buy” rating in a report on Friday, November 11th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $53.11.
BioXcel Therapeutics Company Profile
BioXcel Therapeutics, Inc is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.